cyrilzakka/clinical-trials huggingface dataset:
Self-paced High-intensity Interval Training and Moderate Intensity Continuous Training in Young Adults

Study will be randomized clinical trial. Data will be collected from non probability convenient sampling technique. Total 26 participants from Pakistan Sports Board will be selected and randomly allocated in two different groups i.e. Group A and Group B. Group A will be given high intensity interval training and Group B will be on moderate intensity continuous training. Statistical package for the social sciences will be used to analyze the results by using parametric test after confirming normality of data.

Recreational activities are those in which you genuinely engage with others to have fun and relax in your leisure time. This includes activities that require physical activity as well as connections and play with others. They are not activities that you can finish totally on your alone; while you can try to do some with your own, you will miss out on the enjoyment of doing that with others

High-intensity interval training is a training that cycles between high bursts of activity and predetermined times of less intensive exercise or rest period. The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.

Moderate-intensity continuous training consists of periods followed by 50 minutes of exercise- bicycling, running, jogging, marching, paddling, etc. - at a recorded frequency of 70-75 percent maximal heart rate. The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.

Eligibility Criteria:
Inclusion Criteria:

* Both genders was included in our study.
* Participants of age of 16 to 35 years were included.
* Included those participants who were playing sports such as cricket, football, basketball and tennis and their training workload of less than three training units per week and less than one eight minutes, also doing core strength training, also doing cardio trainings and group exercise, from the last two years.

Exclusion Criteria:

* Adults who were having history of any trauma from last 6 month were excluded.
* SOB or any other cardiopulmonary disease.
ECMO ABI Detection with Hyperfine

The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.

Extracorporeal membrane oxygenation (ECMO) is frequently used to treat refractory cardiovascular and/or respiratory failure. As the support modality has evolved, survival has significantly improved, yet there are high rates of acute brain injury (ABI) in this population due to disease, patient, and treatment factors. This results in significant morbidity and mortality. Specifically, thromboembolic, hypoxic-ischemic, and hemorrhagic complications occur during ECMO support, but the investigators are limited in the monitoring and diagnosis of ABI while on ECMO as currently available imaging modalities (i.e. ultrasound \[US\], computed tomography \[CT\]) have low sensitivity for early hypoxic, cerebrovascular, and ischemic brain injuries. The sensitivity of these modalities increases only when it is too late to effectively intervene. Standard magnetic resonance imaging (MRI) is the gold standard to diagnose stroke and ischemic brain injury but is incompatible with ECMO devices. Swoop (Hyperfine, Guilford, CT) is an FDA cleared ultralow-field portable MRI system that can be used at the bedside and has been studied in critically ill adults with various types of ABI. This novel bedside MRI has been safely operated in clinical environments with equipment that is typically not MRI compatible. A few adult and pediatric ECMO patients have undergone bedside brain MRIs showing feasibility. Yet, what remains unknown is the true prevalence and timing of hypoxic, cerebrovascular, and ischemic brain injuries in pediatric ECMO.

Eligibility Criteria:
Inclusion Criteria

* Participants that will be or are admitted to the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or the Neonatal Intensive Care Unit
* Ages 0-17 years
* Participants that are at high risk for undergoing ECMO or are currently undergoing venovenous or venoarterial ECMO

  • High risk participants include, but are not limited to:
* Undergoing cardiac surgery
* Congenital heart disease
* Congenital diaphragmatic hernia
* Refractory hypoxemic and/or hypercarbic respiratory failure
* Vasoactive-refractory shock

Exclusion Criteria

* Pregnancy
* Active implants such as:

  * Pacemaker
  * Implanted defibrillator
  * Implanted insulin pump
  * Deep brain stimulator
  * Vagus nerve stimulator
  * Cochlear implant
  * Programmable shunt
* MRI incompatible surgical hardware (e.g., staples, screws, etc.)
* Metal-containing tattoos or permanent make-up on head or neck
* Suspected metal in eye, e.g.,
* Former or current welders, metal workers, or individuals with a metal injury
* Metal shrapnel
* Passive implants are considered MRI-conditional
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

This study is a multicentre, open label, non-comparative, two stage phase II trial to assess the activity of ZD1839 (IRESSA) in patients with malignant mesothelioma. Patients will receive trial treatment as first-line therapy, administered continuously once daily until the completion of six 4-week cycles of treatment, disease progression, unacceptable toxicity or withdrawal of consent. Patients continuing to show evidence of response, disease stabilization or clinical benefit from ZD1839 may continue to receive therapy beyond completion of the trail.


Eligibility Criteria:
Inclusion Criteria:

* Histologically-confirmed malignant mesothelioma (based on pleural biopsy); eligibility for first line therapy for malignant mesothelioma
* Uni or bi- dimensionally measurable disease
* No prior radiotherapy within 3 weeks of enrolment into the trial
* No significant comorbid disease

Exclusion Criteria:

* Other malignancies, either co-existing or diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ
* Brian metastasis or leptomeningeal carcinomatosis
* Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy
* Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, or St. John's Wort
Study of FYU-981 in Hyperuricemia With or Without Gout

The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.


Eligibility Criteria:
Inclusion Criteria:

* Hyperuricemic or gout patients
* Serum urate level:

\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL

Exclusion Criteria:

* Gouty arthritis within two weeks before start of study treatment
* Secondary hyperuricemia
* HbA1c: \>= 8.4%
* Uric acid-overproduction type in the classification of hyperuricemia
* History of, clinically significant cardiac, hematologic and hepatic disease
* Kidney calculi or clinically significant urinary calculi
* eGFR: \< 60mL/min/1.73m\^2
* Systolic blood pressure: \>= 180 mmHg
* Diastolic blood pressure: \>= 110 mmHg
rTMS on Diabetic Peripheral Neuropathic Pain

Background: Approximately half of the patients with long-standing diabetes are known to have diabetic peripheral neuropathy (DPN). Pain from DPN deteriorates the quality of life and hinders daily life activities.

Objectives: This study aimed to evaluate the effect of high-frequency (10 Hz) repetitive transcranial magnetic stimulation (rTMS) on the left primary motor cortex (M1) for neuropathic pain in the lower extremities due to DPN.

Methods: In this randomized trial, 22 patients with DPN will randomly assign to the rTMS group (10 Hz stimulation, five sessions) or the sham group. A numeric rating scale (NRS) will use to measure pain intensity before treatment and after 1 day and 1 week of the treatment. Physical and mental health status will evaluate using the Short Form 36-Item Health Survey (SF-36), comprising two subscales (physical and mental component scores \[PCSs and MCSs\]), at 1-week post-treatment.


Eligibility Criteria:
Inclusion Criteria:

* diabetes
* neuropathic pain (stocking glove distribution) of a numeric rating scale (NRS) score of ≥3 (where 0 indicates no pain and 10 indicates the most intense pain imaginable) in the lower extremities
* pain duration of ≥3 months
* age between 21 and 80 years

Exclusion Criteria:

* presence of contraindications for TMS, such as a history of epileptic seizure, presence of metal in the skull, and presence of a cardiac pacemaker.
Cognitive Motivational Behavior Therapy for Gamblers

This study will evaluate the effectiveness of cognitive motivational behavior therapy (CMBT) in treating pathological gamblers.

Pathological gambling is developing into a serious public health problem. The rise in gambling problems has stimulated treatment studies, but little progress has been made. A particular concern is the high dropout rates from treatment studies; gamblers often seek treatment, but fail to complete it and relapse. This study will test the effectiveness of CMBT in helping to increase retention rates in gambling treatment studies.

The first step in this study is designed to enhance gamblers' readiness for change. When participants are committed to change, CMBT will then address specific cognitive biases regarding the notion of randomness, which is thought to lie at the heart of gambling problems. Behavioral components will also be used to enhance gamblers' coping skills.

The participants in this study will be randomly assigned to either CMBT or a Gambler's Anonymous control group. Participants will be assessed prior to and after treatment and at 3- and 6-month follow-up visits. Interviews and questionnaires will be used to assess participants.

Eligibility Criteria:
Inclusion Criteria:

* DSM-IV criteria for pathological gambling
* Eighth grade reading ability
* Reside in the Albany, NY area

Exclusion Criteria:

* Diagnosis of serious psychopathology, including psychosis, bipolar disorder, or alcohol or other substance dependence
Study of TransAeris® System for Enhanced Recovery After Surgery in France

This study will be conducted as a randomized trial of the TransAeris system for the prevention and treatment of ventilator-induced diaphragm dysfunction (VIDD) in patients identified prior to surgery to be at greater risk of prolonged mechanical ventilation (PMV).

This study is a monocentric and open label randomized study in adult open cardiac surgery patients. Eligible patients from whom informed consent is obtained are enrolled in the study. All subjects will be implanted with the TransLoc electrodes during their primary surgery. Patients are randomized to treatment or control groups prior to surgical placement of the TransLoc electrodes.

Comparison will be made between treatment and control patients during the initial 120 hours of study, then comparison of cross-over control patients' EMG from baseline to treatment.

Further comparison of MV Time, ventilator free days and other outcome measures will be made for all patients, over the course of the 30-day treatment period, to literature on an observational basis.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is undergoing an open cardiac procedure by median sternotomy
2. Subject is at risk of prolonged mechanical ventilation according to one or more of the following criteria:

   1. Prior open cardiac surgery
   2. Left Ventricular Ejection Fraction (LVEF) ≤ 30%
   3. History of TIA or CVA
   4. Pre-operative or anticipated intraoperative intra-aortic balloon pump
   5. History of COPD
3. Subject is at least 22 years of age
4. Informed consent has been obtained from the subject
5. Subject is covered by a healthcare insurance

Exclusion Criteria:

1. Subject is on invasive mechanical ventilation prior to procedure
2. Subject has known or pre-existing phrenic nerve paralysis
3. Subject is having a left ventricular assist device (LVAD) implanted
4. Subject has progressive, non-reversible neuromuscular disease affecting the diaphragm
5. Subject is pregnant or lactating
6. Subject is actively participating in another clinical study which could affect outcomes in this study
7. Subject deprived of liberty
8. Subject under court protection
Importing Quality Improvement Practices and Enhance Health Education to Improving Quality of Bowel Preparation

Importing quality improvement practices and enhances health education to improving quality of bowel preparation for health screening colonoscopy

This is a retrospective data analysis study aimed at obtaining the types of purgative treatments used, the results of bowel preparation, and each subject's demographic characteristics (Age \& Gender).

This study aimed to check-up the result and the impact of patient education using a medical team resource management (TRM) method on the adequacy of bowel preparation.

Investigators collected a total of 2,104 (884 female, 1,220 male) healthy subjects who underwent a health check-up colonoscopy screening were enrolled before and after the application of the TRM program intervention. The efficacy of the TRM intervention and the factors affecting bowel preparation were estimated using multivariate logistic regression in this study.

Enrollment of study subjects and data collection: The subjects enrolled in this study were those who received a health check-up colonoscopy screening in a tertiary center, Far Eastern Memorial Hospital (FEMH), in Taiwan from March 2013 to August 2014. A total of 2,104 healthy subjects who underwent check-up colonoscopy screening were enrolled during the pre-intervention, post-intervention, and validation periods. Investigators need to collect each subject's demographic characteristics (Age \& Gender) and the types of purgative treatments used were collected to analyze. According to the Aronchick Bowel Preparation Scale, this study divided the degree of bowel cleansing into four levels, namely, "Excellent", "Good", "Fair" and "Poor". Investigators also need to collect the results of bowel preparation to calculate of the adequate bowel cleansing rate was defined further as the percentage of the participants with "Excellent" or "Good" cleansing in our analysis.

Eligibility Criteria:
Inclusion Criteria:

* The healthy population who received a health check-up colonoscopy screening in Far Eastern Memorial Hospital (FEMH)
* Exam date from March 2013 to August 2014
* Age from 20 y/o to 80 y/o

Exclusion Criteria:

* Gastroenterology outpatients/inpatients
* Missing data subjects
* Out of the Age limits subjects
* Out of the Time period subjects
Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial

This study will measure the efficacy and safety of an early postoperative anticoagulation self-management program, using the CoaguChek S device, in patients undergoing mechanical valve replacements. Patients will be randomized into a study group (self-management) or a control group (physician management).


Eligibility Criteria:
Inclusion Criteria:

* adult patients, 18-70 years of age;
* recipient of a mechanical heart valve (aortic and/or mitral), +/- CABG, +/- postoperative atrial fibrillation.

Exclusion Criteria:

* recipient of a bioprosthetic valve;
* post-operative thrombotic events;
* pre-operative utilization of oral anticoagulation.
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.


Eligibility Criteria:
Inclusion Criteria:

* Man or woman at least 18 years old
* Diagnosis of metastatic colorectal cancer (mCRC)
* One and only one chemotherapy regimen for mCRC consisting of first-line 5-FU -based chemotherapy
* Radiologically documented disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria during treatment or within 6 months of last dose of first-line chemotherapy
* At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST
* Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2
* Paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyses
* Adequate hematologic, renal, and hepatic functions
* Negative pregnancy test within 72 hours of enrollment
* Other protocol-specified criteria may apply

Exclusion Criteria:

* History of or known presence of central nervous system (CNS) metastases
* History of another primary cancer within 5 years of randomization
* Prior irinotecan therapy
* Prior anti-epidermal growth factor receptor (EGFr) antibody therapy or treatment with small molecule EGFr inhibitors
* Any investigational agent or therapy within 30 days before randomization
* Known allergy or hypersensitivity to irinotecan, 5-FU or leucovorin
* History of interstitial lung disease or evidence of interstitial lung disease on baseline chest computed tomography (CT) scan
* Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
* Known positive tests for human immunodefiency virus (HIV), hepatitis C viris (HCV), acute or chronic active hepatitis B virus (HBV)
* Major surgery within 28 days of randomization or minor surgical procedure within 14 days of randomization
* Pregnant or breast-feeding
* Man or woman of child-bearing potential not consenting to use adequate contraceptive methods or abstinence during the course of the study and for 6 months after last study drug administration (women) or 1 month after last study drug administration (men)
* Other protocol-specified criteria may apply
Behavioral Abnormalities in Dysphonic Children

we will assess dysphonic children as regard presence of behavioral abnormalities and then receive voice therapy


Eligibility Criteria:
inclusion criteria :

* dysphonic children age 6-12 years

exclusion criteria:

* age less than 6 years and more than 12 years,
* hearing impaired,
* neurological abnormalities.
Hypertension in Hemodialysis Patients (Aim 3)

We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.

This is a parallel group, active control, single-center, open-label, randomized controlled trial comparing the safety and efficacy of initial therapy with an angiotensin converting enzyme (ACE) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered three times weekly after dialysis.

Eligibility Criteria:
Inclusion Criteria:

1. Patients on chronic hemodialysis for \> 3 mos.
2. Compliance with hemodialysis treatments as defined by less than one missed dialysis per month
3. Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) \>135/75 mm Hg after participation in the ultrafiltration (UF) Trial, or those on no antihypertensive medications but unwilling to do UF Trial.
4. Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) \>104 g/m2 in women and \>116 g/m2 in men.
5. Willingness to give informed consent.

Exclusion criteria:

1. Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months
2. Noncompliance with hemodialysis treatments
3. Known drug abuse
4. Chronic obstructive pulmonary disorder (COPD) requiring home oxygen
5. Congestive Heart Failure Class III or IV.
6. Body mass index \> 40 kg/m2.
7. Known contraindication to atenolol (severe heart failure, bradycardia, bronchial asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or allergy)
Olive Oil Phonophoresis and Chronic Low Back

This study is intended to evaluate the effect of olive oil phonophoresis on chronic law back pain in female athletes.

This study will enroll 60 female patients suffering from chronic low back pain. the study will run in single blind mode that only patients will kept unaware of treatment.

The duration of treatment is 10 days. patients will be assigned randomly to olive oil or placebo group. every day, they will take phonophoresis on lower back using phonophoresis gel as placebo or olive oil as treatment for 10 day. the questionnaires will be filled in baseline visit and day 10. any side effect of drugs or technique will be recorded

Eligibility Criteria:
Inclusion Criteria:

* Young female athletes suffering from low back pain for more than three months

Exclusion Criteria:

* Underlying systematic or visceral disease
* Specific conditions such as neoplasm and fractures, spondylolisthesis
* Previous low back surgery
* Pregnancy
Development of a Computer Assisted Survivor Screening For Adult Survivors of Childhood Cancer

This study will compare two ways of having people respond to a questionnaire about health and emotional well-being: on a computer and with paper and pencil. We will see how long it takes using both methods. We will also ask you how you feel about using a computer to answer the questions.

To determine feasibility of using the Computer Assisted Survivor Screening (CASS) as a routine screening measure for the survivor population. Specifically, to determine patient acceptance, time to completion, and burden associated with the CASS. To examine the potential utility of the CASS as a routine screening measure in the survivor population. To validate the CASS against the SCL-90-R screening measure. Calculate the sensitivity,specificity, positive and negative predictive values, diagnostic agreement and ROC curve of the CASS compared to the SCL-90. Determine the optimal cut-off scores to optimize agreement between the CASS and the SCL-90.

Eligibility Criteria:
Inclusion Criteria:

* Currently at least 18 years of age and not older than 49 years of age
* Diagnosed with first malignancy before the age of 22
* Completed all cancer treatment at least three years prior
* Able to complete the survey instruments in English
* Scheduled for a routine off-treatment follow-up oncology appointment
* Currently disease-free and not receiving any cancer treatment

Exclusion Criteria:

* History of a central nervous system tumor
* A sensory or cognitive impairment that would interfere with completion of the survey
* Currently undergoing treatment by a psychiatrist or psychologist (ie., currently receiving psychotherapy and/or psychotropic medications, as per self-report)